

PRIOR AUTHORIZATION REQUEST FORM
ARANESP®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

- For Medical Pharmacy please fax requests to 801-213-1547
- For Retail Pharmacy requests please fax requests to: 888-509-8142

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans: 855-869-4769, Commercial Groups: 855-859-4892, Advantage U: 888-605-0858

| | | |
|----------------|--------------|-----------------|
| Date: | Member Name: | ID#: |
| DOB: | Gender: | Physician: |
| Office Phone: | Office Fax: | Office Contact: |
| Height/Weight: | HCPCS Code: | |

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Aranesp® (darbepoetin alfa)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

| Questions | Yes | No | Comments/Notes |
|--|--------------------------|--------------------------|-------------------------------------|
| 1. Is the requesting provider a hematologist, oncologist, nephrologist, or in consultation with one? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Does documentation show that the member's hemoglobin is <10 g/dL and/or that the hematocrit is <30%? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 3. Does the member have one of the following indications: <ul style="list-style-type: none"> • Anemia of chronic renal failure, • Anemia due to myelosuppressive chemotherapy with a minimum of 8 additional weeks of planned chemotherapy, • Myelodysplasia or myelodysplastic syndrome? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 4. Does the member have one of the following indications: <ul style="list-style-type: none"> • Request will be used as a substitute for red blood cell transfusion in patients who require immediate correction of anemia, • Uncontrolled hypertension, • Pure Red Cell Aplasia (PRCA) that begins after treatment with erythropoietin drugs? | <input type="checkbox"/> | <input type="checkbox"/> | |

REAUTHORIZATION

| | | | |
|---|--------------------------|--------------------------|--|
| 1. Is the request for reauthorization of therapy? | <input type="checkbox"/> | <input type="checkbox"/> | |
|---|--------------------------|--------------------------|--|

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

| | | | |
|--|--------------------------|--------------------------|-------------------------------------|
| 2. Has the member responded to treatment, demonstrated by an improvement in the hematocrit and hemoglobin levels or a significant decrease in transfusion requirements? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 3. Is current hemoglobin < 11g/dL OR > 10 to <12 g/dL? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc. | | | |
| Additional information: | | | |
| Physician's Signature: | | | |

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 008
 Origination Date: 05/24/2018
 Reviewed/Revised Date: 01/27/2021
 Next Review Date: 01/27/2022
 Current Effective Date: 02/01/2021

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.